Bleeding represents the most important complication of antithrombotic treatment, including
anticoagulant and antiplatelet therapies. A number of scores were proposed to evaluate the risk of bleeding
both for anticoagulant and antiplatelet treatment. In the last decade, 5 bleeding risk scores were published
for use in atrial fibrillation patients, and 3 scores for patients receiving anticoagulants for venous
thromboembolism therapy or prophylaxis. In addition, 3 scores were recently developed to assess inhospital
or short-term bleeding risk in patients receiving antiplatelet therapy after Acute Coronary Syndrome
(ACS) and Percutaneous Coronary Intervention (PCI). Furthermore, 3 additional scores have
focused on long-term bleeding in outpatients receiving dual antiplatelet therapy after PCI. The aim of
this review is to consider the evidence on bleeding scores.
Keywords: Bleeding, clinical predictive rules, atrial fibrillation, venous thromboembolism, acute coronary syndrome, percutaneous
coronary intervention, anticoagulants, antiplatelet therapy.
Rights & PermissionsPrintExport